We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 60% below its sector, cheaper than its peers on earnings.
Standard Chem & Pharm Co. Ltd. (SCP) is a Taiwanese enterprise specializing in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products, nutritional supplements, and Active Pharmaceutical Ingredients (APIs). The company's diverse offerings include medications targeting various therapeutic areas, such as the circulatory, digestive, and respiratory systems. Their portfolio also features antihistamines, central nervous system (CNS) agents, metabolism-regulating drugs, anti-microbial treatments, and topical preparations for skin and mucous membrane conditions. Beyond finished drug products, SCP provides APIs for both human and veterinary applications, as well as various pharmaceutical excipients. Founded in 1967, Standard Chem & Pharm Co. Ltd. maintains its corporate headquarters in Tainan City, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 1720.TW and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
